These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 17380844)

  • 41. Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials.
    Lacourcière Y; Neutel JM; Schumacher H
    Clin Ther; 2005 Nov; 27(11):1795-805. PubMed ID: 16368450
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Heterogeneous effect of calcium antagonists on leg oedema: a comparison of amlodipine versus lercanidipine in hypertensive patients.
    Pedrinelli R; Dell'Omo G; Nuti M; Menegato A; Balbarini A; Mariani M
    J Hypertens; 2003 Oct; 21(10):1969-73. PubMed ID: 14508205
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fixed-dose combination lercanidipine/enalapril.
    Hair PI; Scott LJ; Perry CM
    Drugs; 2007; 67(1):95-106; discussion 107-8. PubMed ID: 17209666
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus.
    Derosa G; Mugellini A; Pesce RM; D'Angelo A; Maffioli P
    BMC Cardiovasc Disord; 2016 Apr; 16():66. PubMed ID: 27068332
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of combination therapy with the angiotensin receptor blocker losartan plus hydrochlorothiazide on brain perfusion in patients with both hypertension and cerebral hemodynamic impairment due to symptomatic chronic major cerebral artery steno-occlusive disease: a SPECT study.
    Saura H; Ogasawara K; Suzuki T; Kuroda H; Yamashita T; Kobayashi M; Terasaki K; Ogawa A
    Cerebrovasc Dis; 2012; 33(4):354-61. PubMed ID: 22433127
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine.
    Guarneri L; Angelico P; Ibba M; Poggesi E; Taddei C; Leonardi A; Testa R
    Arzneimittelforschung; 1996 Jan; 46(1):15-24. PubMed ID: 8821512
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Once-daily nifedipine sustained release (nifelan) on forearm vascular resistance and regression of left ventricular hypertrophy in patients with mild to moderate essential hypertension.
    Chang KC; Cherng WJ
    Changgeng Yi Xue Za Zhi; 1998 Mar; 21(1):28-36. PubMed ID: 9607261
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Postexercise reflex control of forearm vascular resistance during calcium antagonism with slow-release oral isradipine.
    Cléroux J; Kouamé N; Yardley C; Marshall A; Lacourcière Y
    J Cardiovasc Pharmacol; 1992; 19 Suppl 3():S66-9. PubMed ID: 1376840
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine?
    Burnier M; Pruijm M; Wuerzner G
    Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):981-7. PubMed ID: 19619074
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Candesartan cilexetil plus hydrochlorothiazide combination: a review of its use in hypertension.
    Melian EB; Jarvis B
    Drugs; 2002; 62(5):787-816. PubMed ID: 11929332
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antihypertensive effects of lercanidipine in experimental hypertensive rats and dogs.
    Sironi G; Montagna E; Greto L; Bianchi G; Leonardi A; Testa R
    Arzneimittelforschung; 1996 Feb; 46(2):145-52. PubMed ID: 8720303
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Calcium channel blocker effect on insulin resistance and inflammatory markers in essential hypertension patients.
    Farah R; Khamisy-Farah R; Shurtz-Swirski R
    Int Angiol; 2013 Feb; 32(1):85-93. PubMed ID: 23435396
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Differential effects of enalapril-felodipine versus enalapril-lercanidipine combination drug treatment on sympathetic nerve traffic and metabolic profile in obesity-related hypertension.
    Seravalle G; Brambilla G; Pizzalla DP; Casati A; Riva M; Cuspidi C; Bombelli M; Mancia G; Grassi G
    J Am Soc Hypertens; 2016 Mar; 10(3):244-51. PubMed ID: 26831124
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hypertension, possible vascular protection and lercanidipine.
    Ram CV
    Expert Rev Cardiovasc Ther; 2006 Nov; 4(6):783-8. PubMed ID: 17173495
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of delapril plus manidipine compared with enalapril plus hydrochlorothiazide in mild to moderate essential hypertension: results of a randomized trial.
    Mugellini A; Dobovisek J; Planinc D; Cremonesi G; Fogari R
    Clin Ther; 2004 Sep; 26(9):1419-26. PubMed ID: 15531004
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lercanidipine in patients with chronic renal failure: the ZAFRA study.
    Robles NR; Ocon J; Gomez CF; Manjon M; Pastor L; Herrera J; Villatoro J; Calls J; Torrijos J; Rodríguez VI; Rodriguez MM; Mendez ML; Morey A; Martinez FI; Marco J; Liebana A; Rincon B; Tornero F
    Ren Fail; 2005; 27(1):73-80. PubMed ID: 15717638
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combination therapy with lercanidipine and enalapril in the management of the hypertensive patient: an update of the evidence.
    Antza C; Stabouli S; Kotsis V
    Vasc Health Risk Manag; 2016; 12():443-451. PubMed ID: 27895487
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of angiotensin II and losartan in the forearm of patients with essential hypertension.
    Baan J; Chang PC; Vermeij P; Pfaffendorf M; van Zwieten PA
    J Hypertens; 1998 Sep; 16(9):1299-305. PubMed ID: 9746117
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lercanidipine rescues hippocampus pyramidal neurons from mild ischemia-induced delayed neuronal death in SHRSP.
    Sakurai-Yamashita Y; Harada N; Niwa M
    Cell Mol Neurobiol; 2011 May; 31(4):561-7. PubMed ID: 21259046
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cellular and molecular mechanisms of tissue protection by lipophilic calcium channel blockers.
    Menne J; Park JK; Agrawal R; Lindschau C; Kielstein JT; Kirsch T; Marx A; Muller D; Bahlmann FH; Meier M; Bode-Böger SM; Haller H; Fliser D
    FASEB J; 2006 May; 20(7):994-6. PubMed ID: 16597674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.